Research Index
Thymopoietin Research Index
PSI surfaces 50 peer-reviewed studies on Thymopoietin, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
Yuvaraaj VK, Sharma N
Anal Methods·2026·Animal·PubMed →
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
Merlino F, Jia L, Boccino I et al.
J Med Chem·2026·Animal·PubMed →
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
Pfaus JG, Balon R
J Clin Psychopharmacol·2026·Animal·PubMed →
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.
Fuhrman J, Yun J, Indorf A
Expert Rev Clin Pharmacol·2025·Human·Sexual Health·PubMed →
Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study.
Stanley EE, Pfoh E, Lipold L et al.
J Gen Intern Med·2025·Human·Sexual Health·PubMed →
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.
Serilmez M, Abuelrub A, Erol I et al.
Turk J Biol·2025·Animal·PubMed →
A biodegradable suction patch for sustainable transbuccal peptide delivery.
Krupke H, Zoratto N, Rabut L et al.
J Control Release·2025·Animal·PubMed →
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Borland JM, Kohut-Jackson AL, Peyla AC et al.
Neuropharmacology·2025·Animal·PubMed →
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.
Suzuki S, Kitanaka C, Okada M
Anticancer Res·2024·Animal·PubMed →
First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.
Saffati G, Naeem T, Kaaki B et al.
Sex Med·2023·Human·PubMed →
Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.
Safarinejad MR, Hosseini SY
J Urol·2023·Human·PubMed →
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?
Nappi RE, Tiranini L, Cucinella L et al.
Expert Opin Pharmacother·2023·Animal·PubMed →
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA, Kingsberg SA, Portman D et al.
J Womens Health (Larchmt)·2022·Human·Sexual Health·PubMed →
Safety Profile of Bremelanotide Across the Clinical Development Program.
Clayton AH, Kingsberg SA, Portman D et al.
J Womens Health (Larchmt)·2022·Human·Sexual Health·PubMed →
Finding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research.
Kim NN
Sex Med Rev·2022·Animal·PubMed →
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
Spana C, Jordan R, Fischkoff S
Diabetes Obes Metab·2022·Animal·Weight Loss·PubMed →
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
Kingsberg SA, Clayton AH, Portman D et al.
J Sex Res·2021·Human·Sexual Health·PubMed →
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Spielmans GI
J Sex Res·2021·Human·PubMed →
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki P, Revicki D, Wilson H et al.
J Womens Health (Larchmt)·2021·Human·Sexual Health·PubMed →
Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.
Derogatis LR, Revicki DA, Rosen RC et al.
J Patient Rep Outcomes·2021·Animal·PubMed →
Structural insights into ligand recognition and activation of the melanocortin-4 receptor.
Zhang H, Chen LN, Yang D et al.
Cell Res·2021·Animal·PubMed →
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.
Mestria S, Odoardi S, Frison G et al.
Drug Test Anal·2021·Animal·PubMed →
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.
Revicki DA, Althof SE, Derogatis LR et al.
J Patient Rep Outcomes·2020·Animal·PubMed →
Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
Kingsberg SA, Simon JA
J Womens Health (Larchmt)·2020·Animal·Sexual Health·PubMed →
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.
Sauter M, Uhl P, Burhenne J et al.
J Pharm Biomed Anal·2020·Animal·PubMed →
New Drugs 2020, part 2.
Hussar DA
Nursing·2020·Animal·PubMed →
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D et al.
Obstet Gynecol·2019·Human·PubMed →
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S, Derogatis LR, Greenberg S et al.
J Sex Med·2019·Human·Sexual Health·PubMed →
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Simon JA, Kingsberg SA, Portman D et al.
Obstet Gynecol·2019·Animal·PubMed →
Boosting Female Sexual Response by RECONNECTing the Dots.
Carson SA
Obstet Gynecol·2019·Animal·Sexual Health·PubMed →
New Drug for Hypoactive Sexual Desire Disorder in Premenopausal Women.
Aschenbrenner DS
Am J Nurs·2019·Animal·Sexual Health·PubMed →
What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?
Nappi RE, Gardella B
Expert Opin Pharmacother·2019·Animal·PubMed →
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
Clayton AH, Lucas J, DeRogatis LR et al.
Clin Ther·2017·Human·PubMed →
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.
White WB, Myers MG, Jordan R et al.
J Hypertens·2017·Human·PubMed →
Sexual arousal: Sex matters.
Petherick A
Nature·2017·Animal·Neuroprotection, Sexual Health·PubMed →
Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.
Seftel AD
J Urol·2016·Human·PubMed →
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH, Althof SE, Kingsberg S et al.
Womens Health (Lond)·2016·Human·PubMed →
Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.
Lodise NM
Pharmacotherapy·2013·Human·PubMed →
[2013 annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), 28 February-3 March 2013, New Orleans, Louisiana, USA. State of pharmacologial research in Women's Sexual Medicine: From testosterone to bremelatonide].
Buvat J
Gynecol Obstet Fertil·2013·Animal·PubMed →
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.
Nelson ME, Bryant SM, Aks SE
Clin Toxicol (Phila)·2012·Animal·PubMed →
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.
Safarinejad MR, Hosseini SY
J Urol·2008·Human·PubMed →
RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.
Safarinejad MR
J Sex Med·2008·Human·Sexual Health·PubMed →
Gateways to clinical trials.
Tomillero A, Moral MA
Methods Find Exp Clin Pharmacol·2008·Animal·PubMed →
Gateways to clinical trials.
Tomillero A, Moral MA
Methods Find Exp Clin Pharmacol·2008·Animal·PubMed →
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE, Earle DC, Heiman JR et al.
J Sex Med·2006·Human·Sexual Health·PubMed →
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Diamond LE, Earle DC, Garcia WD et al.
Urology·2005·Human·Sexual Health·PubMed →
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR
Methods Find Exp Clin Pharmacol·2004·Human·PubMed →
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
Rosen RC, Diamond LE, Earle DC et al.
Int J Impot Res·2004·Human·Sexual Health·PubMed →
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
Diamond LE, Earle DC, Rosen RC et al.
Int J Impot Res·2004·Human·Sexual Health·PubMed →
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
Molinoff PB, Shadiack AM, Earle D et al.
Ann N Y Acad Sci·2003·Human·Sexual Health, Neuroprotection·PubMed →